Combined Active Treatment in Type 2 Diabetes with NASH
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Empagliflozin (Primary) ; Semaglutide (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COMBATT2NASH
Most Recent Events
- 17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 23 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 31 Jan 2025.